Economic implications of potential drug–drug interactions in chronic pain patients

References

• Airaksinen O, Brox J, Cedraschi C et al. European guidelines for the management of chronic nonspecific low back pain. Eur. Spine J. 15( Suppl. 15), S192–S300 (2006).
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Boswell M, Singh V et al. Comprehensive evidence-based guidelines for interventional techniques in the management of chronic spinal pain. Pain Phys.12(4), 699–802 (2009).
   Google Scholar
• Zhang W, Moskowitz R, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II : OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16(2), 137–162 (2008).
   PubMed Web of Science ®Google Scholar
• Schnitzer T. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin. Rheumatol. 25( Suppl. 25), S22–S29 (2004).
   Google Scholar
• Holmquist G. Opioid metabolism and effects of cytochrome P450. Pain Med. 10(1), S20–S29 (2009).
   Google Scholar
• Facts and Comparisons. In: Principles of drug interactions. Hartshorn E, Tatro D ( Eds). St. Louis, MO (1996).
   Google Scholar
• Martin B, Deyo R, Mirza S et al. Expenditures and health status among adults with back and neck problems. JAMA 299(6), 656–664 (2008).
   PubMed Web of Science ®Google Scholar
• Nimgade A, Mcneely E, Milton D, Celona J. Increased expenditures for other health conditions after an incident of low back pain. Spine 35(7), 769–777 (2010).
   Google Scholar
• Wolf A, Pfleger B. Burden of major musculoskeletal conditions. Bulletin WHO 81(9), 645–656 (2003).
   Google Scholar
• Altman R. Early management of osteoarthritis. Am. J. Manag. Care 16( Suppl.), S41–S47 (2010).
   Web of Science ®Google Scholar
• Grymonpre R, Sitar D. Drug-associated hospital admissions in older medical patients. Am. Ger. Soc. 36(12), 1092–1098 (1988).
   PubMed Web of Science ®Google Scholar
• Jankel C, Mcmillan J, Marin B. Effect of drug interactions on outcomes of patients receiving warfarin or theyophylline. Am. J. Hosp. Pharm. 51(5), 661–666 (1994).
   Google Scholar
• Goldberg R, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am. J. Emerg. Med. 14(5), 447–450 (1996).
   PubMed Web of Science ®Google Scholar
• Juurlink D, Mamdani M, Kopp A, Laupacis A, Redelmeier D. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289(13), 1652–1658 (2003).
   PubMed Web of Science ®Google Scholar
• Suh D, Woodall B, Shin S, Hermes-De Santis E. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann. Pharmacother. 34(12), 1373–1379 (2000).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Monguio R, Otero MJ, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics 21(9), 623–650 (2003).
   PubMed Web of Science ®Google Scholar
• Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy 26(5), 601–608 (2006).
   PubMed Web of Science ®Google Scholar
• Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf. 9(1), 51–59 (1993).
   Google Scholar
• Jankel CA, Speedie SM. Detecting drug interactions: a review of the literature. DICP 24(10), 982–989 (1990).
   Google Scholar
• Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann. Pharmacother. 47(3), 324–332 (2013).
   PubMed Web of Science ®Google Scholar
• Ko Y, Malone DC, Skrepnek GH et al. Prescribers’ knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf.31(6), 525–536 (2008).
   PubMed Web of Science ®Google Scholar
• Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med. Care 40(12), 1161–1171 (2002).
   PubMed Web of Science ®Google Scholar
• Langdorf MI, Fox JC, Marwah RS, Montague BJ, Hart MM. Physician versus computer knowledge of potential drug interactions in the emergency department. Acad. Emerg. Med. 7(11), 1321–1329 (2000).
   PubMed Web of Science ®Google Scholar
• Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 370(9582), 185–191 (2007).
   PubMed Web of Science ®Google Scholar
• Bonnabry P, Despont-Gros C, Grauser D et al. A risk analysis method to evaluate the impact of a computerized provider order entry system on patient safety. J. Am. Med. Inform. Assoc. 15(4), 453–460 (2008).
   Web of Science ®Google Scholar
• Van Rosse F, Maat B, Rademaker CM, Van Vught AJ, Egberts AC, Bollen CW. The effect of computerized physician order entry on medication prescription errors and clinical outcome in pediatric and intensive care: a systematic review. Pediatrics 123(4), 1184–1190 (2009).
   Google Scholar
• Pergolizzi JV, Jr., Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph RH, Summers KH. Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pain Pract. 11(3), 230–239 (2011).
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV, Jr., Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph R, Summers KH. Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions. Pain Pract. 11(4), 325–336 (2011).
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr., Labhsetwar SA, Amy Puenpatom R, Ben-Joseph R, Ohsfeldt R, Summers KH. Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pain Pract. 12(1), 45–56 (2011).
   Google Scholar
• Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA, Ben-Joseph R, Ohsfeldt R, Summers KH. Economic Impact of Potential Drug-Drug I nteractions among Osteoarthritis Patients Taking Opioids. Pain Pract. 12(1), 33–44(2011).
   Google Scholar
• Summers KH, Puenpatom RA, Rajan N, Ben-Joseph R, Ohsfeldt R. Economic impact of potential drug-drug interactions in opioid analgesics. J. Med. Econ. 14(4), 390–396 (2011).
   PubMedGoogle Scholar
• Breedveld FC. Osteoarthritis--the impact of a serious disease. Rheumatology (Oxford) 43( Suppl. 43), i4–i8 (2004).
   PubMedGoogle Scholar
• Rubin DI. Epidemiology and risk factors for spine pain. Neurol. Clin. 25(2), 353–371 (2007).
   PubMed Web of Science ®Google Scholar
• Chou R, Fanciullo GJ, Fine PG et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J. Pain 10(2), 113–130 (2009).
   PubMed Web of Science ®Google Scholar
• Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am. J. Geriatr. Pharmacother. 5(4), 345–351 (2007).
   PubMedGoogle Scholar
• Hellinger FJ, Encinosa WE. The cost and incidence of prescribing errors among privately insured HIV patients. Pharmacoeconomics 28(1), 23–34 (2010).
   Google Scholar
• Preskorn SH. How drug-drug interactions can impact managed care. Am. J. Manag. Care 10(6 Suppl.), S186–S198 (2004).
   Google Scholar
• Bushardt R, Massey E, Simpson T, Ariail J, Siumpson K. Polypharmacy: misleading but manageable. Clin. Interv. Aging 3(2), 383–389 (2008).
   PubMed Web of Science ®Google Scholar
• Richardson K, Ananou A, Lafortune L, Brayne C, Matthews F. Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging 28(7), 547–560 (2011).
   PubMed Web of Science ®Google Scholar
• Mcintyre RS, Jerrell JM. Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study. J. Clin. Psychiatry 70(2), 240–246 (2009).
   Google Scholar
• Constantine RJ, Boaz T, Tandon R. Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. Clin. Ther. 32(5), 949–959 (2010).
   PubMed Web of Science ®Google Scholar
• Feudtner C, Dai D, Hexem KR, Luan X, Metjian TA. Prevalence of polypharmacy exposure among hospitalized children in the United States. Arch. Pediatr. Adolesc. Med.161(1), 9–16 (2011).
   Google Scholar
• Mccance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am. J. Addict.19(1), 4–16 (2010).
   PubMed Web of Science ®Google Scholar
• Qato D, Alexander G, Conti R, Johnson M, Schumm P, Lindau S. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300(24), 2867–2878 (2008).
   PubMed Web of Science ®Google Scholar
• Lessenger JE, Feinberg SD. Abuse of prescription and over-the-counter medications. J. Am. Board Fam. Med. 21(1), 45–54 (2008).
   PubMed Web of Science ®Google Scholar
• Shi CW, Bayard MA. Abuse of over-the-counter medications among teenagers and young adults. Am. Fam. Physician 84(7), 745–750 (2011).
   Google Scholar
• Levine DA. “Pharming”: the abuse of prescription and over-the-counter drugs in teens. Curr. Opin. Pediatr. 19(3), 270–274 (2007).
   PubMed Web of Science ®Google Scholar
• Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat. Report (12), 1–23 (2008).
   Google Scholar
• Raphael J, Hester J, Ahmedzai S et al. Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med. 11(6), 872–896 (2010).
   PubMed Web of Science ®Google Scholar
• Denneson LM, Corson K, Dobscha SK. Complementary and alternative medicine use among veterans with chronic noncancer pain. J. Rehabil. Res. Dev. 48(9), 1119–1128 (2011).
   PubMed Web of Science ®Google Scholar
• Zakrzewski-Jakubiak H, Doan J, Lamoureux P, Singh D, Turgeon J, Tannenbaum C. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome P450-based software. Am. J. Geriatr. Pharmacother. 9(6), 461–470(2011).
   PubMed Web of Science ®Google Scholar
• Hines LE, Saverno KR, Warholak TL et al. Pharmacists’ awareness of clinical decision support in pharmacy information systems: an exploratory evaluation. Res. Soc. Adm. Pharm.7(4), 359–368 (2011).
   PubMed Web of Science ®Google Scholar
• Saverno KR, Hines LE, Warholak TL et al. Ability of pharmacy clinical decision-support software to alert users about clinically important drug–drug interactions. J. Am. Med. Inform. Assoc. 18(1), 32–37 (2011).
   PubMed Web of Science ®Google Scholar
• Ko Y, Abarca J, Malone DC et al. Practitioners’ views on computerized drug-drug interaction alerts in the VA system. J. Am. Med. Inform. Assoc. 14(1), 56–64 (2007).
   PubMedGoogle Scholar
• Malone DC, Saverno KR. Evaluation of a wireless handheld medication management device in the prevention of drug-drug interactions in a Medicaid population. J. Manag. Care Pharm. 18(1), 33–45 (2012).
   Google Scholar
• Food and Drug Administration. Drug interaction studies: study design, data analysis, implications for dosing, and labeling recommendations. In: Guidance for Industry, Rockville, MD (2012).
   Google Scholar
• Rascati KL, Smith MJ, Neilands T. Dealing with skewed data: an example using asthma-related costs of medicaid clients. Clin. Ther. 23(3), 481–498 (2001).
   Google Scholar